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LDL size and subclasses in patients with abdominal aortic
aneurysm
Abstract
Since the type of dyslipidemia in patients with abdominal aortic aneurysm (AAA) is still insufficiently
defined, we measured plasma lipids and analyzed LDL size and subclasses by gradient gel
electrophoresis in 30 male patients (69+/-6 years, BMI: 27+/-3) with newly diagnosed AAA and in 26
age- and BMI-matched male healthy controls. Patients with AAA had lower HDL-cholesterol
(p<.0001), increased triglycerides (p=.0002) and smaller LDL size (p<.0001) as well as increased levels
of total small, dense LDL (p=.0210) in relation to controls. Multivariate analysis also showed that small
LDL size was independently associated with the presence of AAA (p=.0350). Increased levels of small,
dense LDL may therefore represent a common feature in patients with AAA.
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Abstract
Since the type of dyslipidemia in patients with abdominal aortic aneurysm (AAA) is still insufficiently defined, we measured plasma
lipids and analyzed LDL size and subclasses by gradient gel electrophoresis in 30 male patients (69±6 years, BMI: 27±3) with newly
diagnosed AAA and in 26 age- and BMI-matched male healthy controls. Patients with AAA had lower HDL-cholesterol (pb .0001),
increased triglycerides (p=.0002) and smaller LDL size (pb .0001) as well as increased levels of total small, dense LDL (p=.0210) in
relation to controls. Multivariate analysis also showed that small LDL size was independently associated with the presence of AAA
(p=.0350). Increased levels of small, dense LDL may therefore represent a common feature in patients with AAA.
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1. Introduction
The prevalence and type of dyslipidemia in patients with
abdominal aortic aneurysm (AAA) are still insufficiently
defined. Patients with AAA may show lower high-density-
lipoproteins (HDL)-cholesterol levels and higher triglycer-
ides concentrations [1], two lipid abnormalities usually
accompanied by increased levels of small, dense LDL [2]. In
fact, both the quality and the quantity of low-density-
lipoproteins (LDL) seem to exert a direct influence on
cardiovascular risk and LDL comprise multiple distinct
subclasses with at least four major subspecies: large LDL-I,
medium LDL-II, small LDL-III and very small LDL-IV [2].
LDL size is an important predictor of cardiovascular
events and progression of coronary heart disease (CHD) and
its predominance has been accepted as an emerging
cardiovascular risk factor [3]. Yet, LDL size and subclasses
have not been assessed in patients with AAA, a category of
subjects carrying a CHD risk equivalent to those with
established CHD and this potentially limits the utility of
information we have on this category of high-risk subjects.
Therefore in the present study we investigated whether
patients with AAA have reduced LDL size or increased levels
of small, dense LDL.
2. Methods
2.1. Patients and control subjects
Approximately 1500 patients undergoing catheter angio-
graphy during a period of ten months at our Angiographic
Unit were evaluated according to the following inclusion
criteria: male gender and the presence of AAA. According
to these inclusion criteria we identified as potentially
eligible for our study 104 patients. We then excluded
patients with renal or hepatic diseases able to modify
plasma lipoproteins, those using hypolipidemic drugs and
CHD patients because they show peculiar plasma lipopro-
teins alterations [2]. According to these criteria we included
in our study 30 subjects with newly diagnosed AAA after
giving informed written consent. As controls we selected a
group of 26 healthy male subjects, recruited from family
members of hospital co-workers, matched for age and body
mass index (BMI) with the same exclusion criteria
described above. None of them used hypolipidemic drugs
in the last 12 months before starting the study. The study
protocol was reviewed and approved by the local Ethics
Committee.
Among main cardiovascular risk factors, hypertension
(systolic or diastolic blood pressure respectively higher than
140 and 90 mmHg or pharmacological therapy with
antihypertensive drugs), diabetes (fasting glucose plasma
concentrations N126 mg/dl or pharmacological therapy with
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antidiabetic drugs or insulin) and smoking habits were
recorded. BMI was calculated as kg/m2.
2.2. Laboratory analyses
Plasma lipids were measured by standard enzymatic–
colorimetric methods in fasting plasma. For patients with
AAA blood samples were collected before the angiography.
LDL size and subclasses were assessed by whole plasma 2–
16% nondenaturing polyacrylamide gradient gel electro-
phoresis, as previously described [4]. LDL subclass
distribution (LDL-I, IIA, IIB, IIIA, IIIB, IVA and IVB)
was calculated as percentage of total LDL.
2.3. Statistical analysis
Statview 5.0 (SAS Institute, NC, USA) was used to
perform non-parametric Mann–Whitney test for numeric
variables and McNemar test for nominal variables. Multi-
variate analysis was performed by stepwise multiple
regression in order to assess possible clinical and laboratory
variables independently associated with the presence of
AAA.
3. Results
AAA showed higher prevalence of hypertension
(pb .0001), smoking (pb .0001) and diabetes (p=.0023)
with lower HDL-cholesterol (pb .0001) and increased
triglycerides (p=.0002) (Table 1). AAA also had smaller
LDL size (pb .0001) due to reduced LDL-I (pb .0001) and
increased LDL-IIB (pb .0001), -IIIA (pb .05) and -IVB
particles (pb .05) (Fig. 1), with higher levels of total small,
dense LDL (p=.0210).
Multiple regression analysis (data not shown) revealed
that among all investigated parameters (including age, BMI,
smoking, diabetes, hypertension, plasma lipids and LDL size
and subclasses) only HDL-cholesterol (p=.002), smoking
(p= .013) and LDL size (p= .035) were independently
associated with the presence of AAA.
4. Discussion
This is the first study reporting that patients with AAA,
beyond plasma lipid alterations, have smaller LDL size due
to increased small, dense particles. Multivariate analysis also
showed that, beyond smoking and low HDL-cholesterol,
small LDL size was independently associated with the
presence of AAA. However, observational prospective
studies are needed to test whether increased levels of
small, dense LDL represent a risk factor for AAA, and if so
Table 1
Clinical and laboratory characteristics in all subjects (as mean±SD).
Controls (n=26) P= AAA (n=30)
Age (years) 68.7±4.9 ns 68.8±5.8
BMI (kg/m2) 26.9±2.1 ns 27.4±3.3
Hypertension (n,%) 4 (15) b .0001 20 (67)
Smoking (n,%) 5 (19) b .0001 21 (70)
Diabetes (n,%) 0 (0) .0023 9 (30)
Total-cholesterol (mmol/L) 4.22±0.48 ns 4.47±0.80
Triglycerides (mmol/L) 1.13±0.42 .0002 1.74±0.66
HDL-cholesterol (mmol/L) 1.21±0.18 b .0001 0.83±0.18
LDL-cholesterol (mmol/L) 2.49±0.54 ns 2.84±0.77
LDL size (Å) 275±7 b .0001 263±8
Total small, dense LDL (%) 28±6 .0210 34±9
Fig. 1. Mean LDL subclasses in the two groups.
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whether therapy focused on such lipid abnormality may
lower the incidence or progression of AAA.
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Post-cardiotomy cardiogenic shock occurs following 2–6%
of adult cardiac procedures. [1] The typical initial treatment
strategy includes the use of inotropic pharmacological agents
and intra-aortic balloon pump (IABP) support but despite this
mortality remains as high as 60%. [2] Therefore attention has
turned to the use of ventricular assist devices (VAD), which
are capable of restoring normal haemodynamics and organ
perfusion even in the case of complete myocardial pump
failure. The use of these devices for long-term support as a
bridge-to-transplantation is well established [3], however the
use of VADs post-cardiotomy as a bridge-to-recovery is still
under evaluation.
The ideal VAD should be easy to prime, implant, manage
and explant; capable of high flows; relatively inexpensive
and be able to operate with little or low dose anticoagulation
for more than 24 h. Following previous work at our insti-
tution [4] we propose the Levitronix Centrimag magneti-
cally levitated, centrifugal pump device for such a purpose.
We describe the successful use of the Levitronix centrifugal
pump as a bridge-to-recovery in two patients with post-
cardiotomy cardiogenic shock.
1. Case one
A 48-year-old woman with severely impaired left ventri-
cular function (LVEF 27%) and moderate to severe mitral
regurgitation (MR) was referred for surgical revascularisa-
tion and mitral valve repair. She had developed angina in
February 2006 and an angiogram in April 2006 revealed
100% LAD and severe RCA stenosis. She received angio-
plasty and stent to the LAD. Two weeks later her anginal
symptoms returned and she underwent further stenting to the
LAD for in-stent stenosis and stenting of the RCA. Two
months later she underwent elective open cholecystectomy
and suffered a peri-operative myocardial infarction and was
admitted to the intensive care unit (ICU) in cardiogenic
shock. After recovering from this episode she underwent
further angiography which revealed 90% in-stent LAD and
RCA stenoses. Dobutamine stress echocardiography reveal-
ed poor anterior and apical LV segments with viable basal
segments, moderate MR and moderate pulmonary hyperten-
sion. Cardiac MRI revealed 9 of 17 viable myocardial seg-
ments with 3 hibernating segments.
The patient underwent uneventful two-vessel coronary
artery bypass grafting [LIMA to LAD and SVG to RCA] and
mitral valve repair (28 mm ETLogix annuloplasty ring) and
was separated from cardiopulmonary bypass in sinus rhythm
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